$NBIX News

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

Where Will Neurocrine Biosciences Be in 5 Years?

Expert Publication On PWS Treatment Could Be A Game Changer For Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Trial

Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome

Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease

Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026

Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

Axsome Therapeutics (AXSM) vs. Neurocrine Biosciences (NBIX): Is Faster Growth Worth Paying More For?

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock

Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference